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Abstract
Background: Genome-wide studies have shown that polymorphisms on chromosome 4q25, 16q22 and 1q21 correlate with
atrial fibrillation (AF). However, the distribution of these polymorphisms differs significantly among populations.
Objective: To test the polymorphisms on chromosome 4q25, 16q22 and 1q21 in a group of patients (pts) that underwent
catheter ablation of AF.
Methods: Four hundred and ten patients with AF that underwent pulmonary vein isolation were included in the study.
Control group (n=550) was taken from healthy population, matched for age, sex and presence of hypertension. All
participants were genotyped for the presence of the rs2200733, rs10033464, rs17570669, rs3853445, rs6838973 (4q25),
rs7193343 (16q22) and rs13376333 (1q21) polymorphisms.
Results: All the polymorphisms tested (except rs17570669) correlated significantly with AF in univariate analysis (p values
between 0.039 for rs7193343 and 2.7e-27 for rs2200733), with the odds ratio (OR) 0.572 and 0.617 for rs3853445 and
rs6838973, respectively (protective role) and OR 1.268 to 3.52 for the other polymorphisms. All 4q25 SNPs tested but
rs3853445 were independently linked with AF in multivariate logistic regression analysis. In haplotype analysis six out of
nine 4q25 haplotypes were significantly linked with AF. The T allele of rs2200733 favoured increased number of episodes of
AF per month (p=0.045) and larger pulmonary vein diameter (recessive model, p=0.032).
Conclusions: Patients qualified for catheter ablation of AF have a significantly higher frequency of 4q25, 16q22 and 1q21
variants than the control group. The T allele of rs2200733 favours larger pulmonary veins and increased number of episodes
of AF.
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Introduction
From the epidemiological perspective atrial fibrillation (AF)
represents the most serious problem of all cardiac arrhythmias due
to its high prevalence and association with increased risk of stroke,
heart failure, and death [1]. The mean annual healthcare cost of a
patient with AF in European countries ranges from 1000 to 3200
EUR [2]. The treatment of AF has significantly changed in the
past decade due to the introduction of ablation which offers a
potential curative strategy for patients with paroxysmal, persistent,
or permanent atrial fibrillation [3].
Several genetic loci responsible for familial AF have been
identified, such as potassium- and sodium-channel genes [4,5,6],
but they account for only a small fraction of all AF cases. A recent
genome-wide association study has identified variants on chromo-
some 4q25 that predispose to AF and are relatively common. In
particular, two single-nucleotide polymorphisms (SNPs),
rs2200733 and rs10033464, have been pointed out as markers
most strongly associated with the disease. The association between
AF and rs2200733/ rs10033464 has been observed in Icelandic,
Swedish, USA and Chinese [7] populations as well as the
population of the Framingham Heart Study and several other
Western European populations [8]. Later on several other SNPs
on chromosome 4q25 (rs17570669, rs3853445, rs6838973) were
found, but also other loci on 16q22 (rs7193343) and 1q21
(rs13376333) [9,10,11]. These correlations have not been studied
in the Polish population until now.
Since the 4q25 haplotype block is located about 100–200
thousand base pairs away from known genes, its functional
significance is not known. The closest gene is PITX2 encoding a
transcription factor that influences heart development, especially
the pulmonary veins [7]. rs7193343 is an intronic SNP located in
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[10], while SNP rs13376333 is located in an intron of the calcium
activated potassium channel KCNN3 gene [11].
The aim of our study was (a) to determine the association
between variants on chromosome 4q25, 16q22 and 1q21 and AF
in a highly selected group of Polish patients that underwent
pulmonary vein isolation, and (b) to explore the putative influence
of those variants on left atrium diameter (antero-posterior),
pulmonary vein diameter and presence of patent foramen ovale
(PFO), as well as several clinical parameters such as paroxysmal-
persistent AF, coexistence of atrial flutter (AFL), AF burden
(number of episodes of AF), age of onset of AF, and frequency of
lone AF.
Methods
We performed a case-control study.
Description of the case group
The study comprised 410 consecutive patients with AF
(paroxysmal or persistent) that underwent pulmonary vein
isolation in the years 2006–2009. Inclusion criteria: symptomatic
AF without reversible cause, unsuccessful treatment with at least
one antiarrhythmic drug (group Ic or III), age below 70 years.
Exclusion criteria: hyperthyroidism, significant mitral stenosis/
insufficiency, left atrial dimension over 5.5 cm, severe disease with
life expectancy below 1 year. Before each procedure patients
underwent either transesophageal echocardiography or computer
tomography of the left atrium.
The study was approved by the Bioethics Committee of the
Medical University of Warsaw and all patients gave written
informed consent.
The following clinical parameters were recorded: presence of
hypertension, coronary disease, heart failure, diabetes, history of
hyperthyroidism. Patients were also asked about the year of the
onset of AF and mean number of episodes of AF per month
(within the last 6 months). Presence of concomitant atrial flutter
(AFL) was defined as at least one episode of AFL with a typical
ECG pattern. Definitions of paroxysmal, persistent and lone AF
were according to the European guidelines [12]. Diagnosis of
patent foramen ovale (PFO) was based on transesophageal
echocardiography (TEE). Measurements of pulmonary vein
diameters were based on TEE, only examinations made by the
same operator (n=209) were included in the subanalysis.
Description of the control group
DNA samples from controls were obtained from a bank of
samples collected during a recent Polish population-wide health
survey WOBASZ (Wieloos ´rodkowe ogo ´lnopolskie badanie stanu
zdrowia ludnos ´ci, National Polish Health Survey [13]). The
control group (n=550) included subjects from background
population that did not have a history of atrial fibrillation or
cardiac arrhythmia, and was matched for age, sex and presence of
hypertension with the patients. The study of the WOBASZ cohort
was approved by The Medical Ethics Committee of National
Institute of Cardiology in Warsaw. Each participant gave two
written consents: for use of questionnaire data and for taking blood
sample for DNA isolation and genetic analyses.
Genotyping
Genomic DNA was isolated from peripheral blood by
salting out. Genotyping of SNPs: rs2200733, rs10033464,
rs17570669, rs3853445, rs6838973, rs7193343 and rs13376333
was performed using Taqman Assays (C_16158671_10, Custom
TaqMan SNP Genotyping Assay, C__33254659_10, C__
1176985_10, C__29128132_20, C__29343982_10 and C__
2745708_10 respectively) (Applied Biosystems, Foster City,
California, USA). Assays were performed according to the
manufacturer’s instructions using a 7500 Real-Time PCR
System (Applied Biosystems).
Statystical analysis
Continuous variables are presented as mean 6SD (standard
deviation) or median (1–3 quartile), depending on variable
distribution. Categorical variables are presented as frequencies.
The Chi2 or Fisher exact tests were used to test deviations of the
genotype distribution from Hardy–Weinberg equilibrium and to
compare allele and genotype frequencies between groups. Effects
of genotypes on continuous parameters were analyzed by one-way
ANOVA or relevant non-parametric tests (Kruskal-Wallis).
Comparison of diameters of pulmonary veins in the recessive
model, due to significant deviations from normal distribution, was
performed with Mann-Whitney U test. Multivariate logistic
regression was performed to assess independent significance of
all 4q25 polymorphisms. Haplotype analysis was performed with
PLINK software [14].
Sample size calculation (post-hoc) was performed using top
4q25 polymorphisms (rs2200733 and rs10033464). Based on
previous results we assumed polymorphic allele frequency of
rs10033464 equal to 0.08 for controls and 0.12 for cases, and for
rs2200733 0.11 and 0.17, respectively [7]. At alpha=0.05 to
achieve 80% power with the controls/cases ratio=1.5, the
minimal number of cases and controls was 365 and 545 for
rs10033464, and 225 and 335 for rs2200733.
Results
The characteristics of the patients and controls is shown in
table 1. There were no statistically significant differences between
the two groups with respect to age, sex and presence of
hypertension (table 1). Among both patients and controls the
genotype distribution did not deviate from Hardy–Weinberg
equilibrium (from 0.035 and 0.045 for rs7193343 and rs6838973
Table 1. Characteristics of study and control groups.
cases controls
Age* 53.3 (11.3) 53.1 (10.4)
Women 128 (31.2) 169 (30.7)
Hypertension 234 (57.1) 310 (56.4)
Diabetes 35 (8.5) ND
Coronary disease 40 (9.8) 0 (0)
Heart failure 6 (1.5) 0 (0)
History of hyperthyroidism 85 (20.7) ND
Current smoker 17 (4.1) 187 (34)
Hyperlipidemia 86 (21.5) ND
Family history 13 (3.2) NA
Age of AF diagnosis* 46.7 (10.7) NA
Data presented as: n (%).
*mean (SD).
SD – standard deviation.
ND – no data; NA – not applicable.
doi:10.1371/journal.pone.0021790.t001
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Bonferroni correction], to 1.00 in rs13376333 cases group).
For all SNPs with the exception of rs17570669 there was a
statistically significant difference in polymorphic allele frequencies
between cases and controls (table 2). Pairwise analyses among the
4q25 SNPs showed a weak LD (r
2,=0.1) except for rs3853445–
rs6838973 (r
2,0.4, both among cases and controls, table 3). In
multivariate logistic regression analysis, rs6838973 was significant-
ly associated with AF (OR 0.608; 95% CI 0.475–0.778;
p=0.000079) whereas rs3853445 was not (OR=0.9, p=0.43).
To further study independence of effects of 4q25 SNPs on AF risk
a multivariate logistic regression model was built including
rs2200733, rs10033464, rs17570669 and rs6838973. All four
SNPs were found to be associated with AF: in the case of
rs2200733 and rs10033464 the effects were in the direction of
increased risk (OR=3.743, p=1.21E-20 and OR=2.362 and
P=2.12E-06, respectively) whereas for rs17570669 and rs6838973
protective effects were observed (OR=0.608, p=0.046 and
OR=0.661, p=0.00033, respectively, table 4).
When analysis of haplotypes was performed a highly statistically
significant overall association was observed (P=1.86E-32, omni-
bus test of haplotype association). The strongest effect was
conferred by the TGAC haplotype which had a frequency of
0.257 among cases vs. 0.074 among controls, conferred a relatively
high risk for AF (OR=4.33) and was highly significantly
associated with the disease (p=1.187E-27, table 5).
There was a statistically significant correlation between rs2200733
and the number of AF episodes per month (p=0.045, one way
ANOVA). The mean number of AF episodes (95% CI) was 7.3 (5.4–
9.1), 8.8 (6.8–10.8) and 12.9 (8.8–16.3) for patients with the CC, CT
and TT genotypes, respectively. The haplotype with the strongest
link with AF (TGAC, see table 5) was the only one significantly
linked with the number of AF episodes (beta=3.04, p=0.0048).
We also observed a statistically significant correlation between
the rs2200733 genotypes and pulmonary vein diameter in a
recessive model (p=0.032, Mann-Whitney U test for mean value
of all pulmonary veins). Age or sex did not affect significantly the
pulmonary vein diameter. The correlation was significant for the
left inferior pulmonary vein whereas there was a trend for the left
and right superior and no effect for the right inferior pulmo-
nary vein (table 6). None of the other polymorphisms (rs10033464,
rs17570669, rs6838973, rs3853445, rs7193343, rs13376333) cor-
related with the number of AF episodes nor with diameter of
pulmonary veins (data not shown).
We did not see any correlation of the polymorphsims tested with
concomitant diseases (hypertension, diabetes, coronary disease,
heart failure) or with the frequency of lone AF, persistent AF, AFL
coexistence, age of diagnosis of AF, or left atrial diameter (data not
shown).
Discussion
Our results provide a strong confirmation of the association
between AF and 4q25, 16q22 and 1q21 variants, in particular
rs2200733 for which the statistical significance of the observed
association (p=2.7610
227) exceeded the threshold used for
genome-wide studies. We also provide the first confirmation of
Table 2. Genotype distribution of analyzed SNPs among patients and controls.
chromosome SNP Minor allele Patients Controls OR CI p
4q25 rs2200733 T 39/173/177 12/109/425 3.369 2.633–4.31 4.526e-22
4q25 rs10033464 T 3/87/295 2/79/460 1.695 1.23–2.335 0.001253
4q25 rs17570669 T 0/46/364 5/69/477 0.7725 0.532–1.122 0.1751
4q25 rs3853445 C 16/122/272 44/215/296 0.6227 0.5003–0.7751 2.232e-5
4q25 rs6838973 T 42/185/172 131/241/158 0.575 0.4756–0.695 1.074e-8
1q21 rs13376333 T 45/172/159 53/200/280 1.328 1.087–1.622 0.0054
16q22 rs7193343 T 27/128/230 28/148/344 1.268 1.012–1.590 0.039
Number of polymorphic homozygotes/polymorphic heterozygotes/wild types are given. OR – odds ratio. CI – 95% confidence interval (calculated by univariate logistic
regression assuming additive model).
doi:10.1371/journal.pone.0021790.t002
Table 3. Pairwise linkage disequilibrium (LD) scores (r2)
among 4q25 SNPs.
Patients
rs2200733 rs10033464 rs17570669 rs3853445
rs10033464 0.05
rs17570669 0.03 0.02
rs3853445 0.04 0.07 0.03
rs6838973 0.03 0.01 0.13 0.39
Controls
rs10033464 0.01
rs17570669 0.08 0.01
rs3853445 0.0000 0.05 0.10
rs6838973 0.003 0.03 0.08 0.42
doi:10.1371/journal.pone.0021790.t003
Table 4. Multivariate logistic regression of 4q25 SNPs with
independent effects on AF risk.
OR CI p
rs2200733 3.743 2.836–4.941 1.21e-20
rs10033464 2.362 1.656–3.370 2.12e-6
rs17570669 0.608 0.373–0.991 0.046
rs6838973 0.661 0.528–0.829 0.00033
OR – odds ratio; CI – confidence interval.
doi:10.1371/journal.pone.0021790.t004
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rs3853445 and rs6838973 were both associated with AF but most
likely were markers of a single primarily associated variant. Our
data suggest that rs6838973 might be in a stronger LD with this
primary variant as in our data it accounted for the association of
rs3853445. We also confirmed the observation [9] that
rs17570669, while not associated with AF in a univariate analysis,
has a protective effect in an analysis adjusted for other markers in
the 4q25 region. In contrast to Lubitz et al. [9] but in agreement
with earlier results [7,8] we observed a strong independent
susceptibility conferring effect of rs10033464. The association of
SNPs on 16q22 and 1q21 with AF is the first confirmation of the
results by Gudbjartsson [10] and Ellinor [11].
Our AF group was homogenous and well described. It
comprised consecutive patients, thus reflecting everyday clinical
practice. The control group was matched with the patients
regarding region of birth, age, sex and presence of hypertension.
The frequency of the polymorphic alleles in the control group was
comparable to those found in other studies [7,8].
Comparing with the previous studies in European populations,
the frequency of the polymorphic rs2200733 allele in the Polish AF
group was relatively high. A German group with lone AF [8] and
another German group that underwent catheter ablation [15] had
lower frequency of the T allele (0.27). There are three major
differences between our group and the non-ablation groups – (i)
our patients were highly symptomatic, (ii) had a high burden of AF
(many patients had paroxysms of AF almost every day) and (iii)
were drug-resistant. In particular, our results support the
importance of the burden of AF – patients with the T allele of
rs2200733 had more paroxysms of AF per month than did patients
with the C allele, which could explain why such patients are
overrepresented in the group qualified for catheter ablation. That
observation was confirmed in haplotype analysis – the TGAC
haplotype (see table 5) with the strongest relationship with AF was
the only one linked with the number of AF episodes. The
frequency of three other polymorphisms form the 4q25 region was
comparable to that in other AF populations of European ancestry
[7,8,10]. In a logistic regression analysis we found that all 4q25
polymorphisms tested were independently linked with AF. We
identified nine 4q25 haplotypes, of which six were significantly
linked with AF.
We also confirmed other independent markers of AF: rs7193343
on chromosome 16q22 and rs13376333 (1q21). Although only
about 30% of our group had lone AF, the frequency of rs13376333
was comparable to that in a population with lone AF [11]. The
frequency of rs7193343 was comparable to that found in a previous
study [10].
We observed that patients with the T allele of rs2200733 had a
larger diameter of pulmonary veins, in particular when the genetic
effect was modeled as recessive. That could be related to the earlier
observation that patients with the T allele have more recurrences
after catheter ablation [15], although it has been shown that the
diameter of pulmonary veins has no impact on the outcome of
catheter ablation [16]. The problem needs further studies.
The mechanisms of the effect of the 4q25 genetic variants on AF
is not clear. The nearest gene is PITX2 (Paired-like homeodomain
transcription factor 2), important for determining the left–right
asymmetry and for the differentiation of the left atrium [17].
PITX2c-deficient mice do not develop pulmonary myocardial
sleeves [18] – clinical studies have demonstrated that those sleeves
generate ectopic beats that play a substantial role in initiating and
maintaining atrial fibrillation [19]. Electrical isolation of those
sleeves in pulmonary veins is a cornerstone for most AF ablation
procedures [20]. The 1q21 locus is at the KCNN3 gene which
codes for a member of a family of calcium-activated potassium
channels [11]. It has been shown on an animal model that KCNN
plays a role in atrial action potential duration [21] – shortening of
action potential duration is an important mechanism for the
development and maintenance of the AF. rs7193343 is an intronic
SNP located in the zinc finger homeobox 3 (ZFHX3) gene
(chromosome 16q22) [10]. The gene may play a role in regulation
of growth and differentiation of neuronal and skeletal muscle [22],
but its relation to AF is unknown.
Limitations of the study
The main limitation of the study is connected with the high
number of hypotheses tested in the exploration of novel genotype
–phenotype correlations. Therefore all the observations regarding
new associations/correlations should be verified in adequately
powered dedicated studies.
Conclusions
Polish patients qualified for catheter ablation due to AF have a
significantly higher frequency of 4q25 (especially rs2200733), 16q22
and1q21 variantsthan thecontrolgroup.The T alleleofrs2200733
seems to favour larger pulmonary veins and a higher number of
episodes of AF but it should be verified in future studies.
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Table 6. Correlation of rs2200733 genotype (CC and CT vs.
TT) with diameter of pulmonary veins (in millimetres).
Pulmonary veins CC and CT TT p
Left superior 16 (14–18) 17.5 (15–19) 0.127
Left inferior 16 (14–18) 17 (16.0–19) 0.012
Right superior 17 (15–19) 18 (16–20) 0.101
Right inferior 17 (15–19) 17.3 (16–20) 0.330
Mean value 16.25 (15–18.25) 18 (16.75–19.5) 0.032
For calculation a recessive effect was assumed.
Data presented as median (1
st–3
rd quartile).
doi:10.1371/journal.pone.0021790.t006
Table 5. Haplotypes found for 4q25 SNPs with independent
effects on AF risk (i.e. rs2200733-rs10033464-rs17570669-
rs6838973 haplotypes).
Haplotype Patients Controls OR p
TGTT 0.035 0.031 1.14 0.6266
CGTT 0.017 0.039 0.44 0.006895
CTAT 0.061 0.052 1.17 0.4411
TGAT 0.028 0.014 1.96 0.04009
CGAT 0.199 0.337 0.49 5.08e-11
CTAC 0.059 0.025 2.49 0.000147
TGAC 0.257 0.074 4.33 1.18e-27
CGAC 0.345 0.428 0.70 0.000273
TGTT 0.035 0.031 1.14 0.6266
doi:10.1371/journal.pone.0021790.t005
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